Abstract The phosphatidylinositol 3-kinase (PI3-K)/Akt pathway is involved in various malignancies, but the role of PI3-K/Akt pathway in Epstein-Barr virus (EBV) infected Burkitt's lymphoma (BL) cells remains unclear. To elucidate therapeutic targets for BL, this study investigates the effect of PI3-K/Akt pathway in: EBV-positive BL cell lines Raji, P3HR-1, Akata and Daudi; and EBV-negative BL cell lines Ramos and BJAB. Results of analyses indicate that Akt was constitutively phosphorylated in BJAB, P3HR-1, Akata, and Daudi but not in Ramos and Raji cells. We characterized Akt phosphorylation on cell growth and EBV lytic cycle in P3HR-1 cells, which were phosphorylated most intensively. The Akt was equally phosphorylated in cells cultured with and without fetal bovine serum for a few days. Akt phosphorylation and cell growth were inhibited by PI3-K specific inhibitor LY294002 in a dosedependent manner. LY294002 markedly down regulated expression of EBV lytic gene BRLF1 protein Rta, BMRF1 protein EA-D, but not BZLF1 protein ZEBRA. The inhibitor reduced viral capsid antigen (VCA) positive cells. Down regulation of Rta by LY294002 occurred at the transcriptional level. These results demonstrate that PI3-K/ Akt pathway is activated constitutively in P3HR-1 cells; it promotes cell growth and the lytic cycle cascade downstream of ZEBRA.
Introduction
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that infects more than 90% of the global adult population. The virus causes infectious mononucleosis and is associated with various malignancies such as Burkitt's lymphoma (BL), Hodgkin's lymphoma, and nasopharyngeal carcinoma [as reviewed in references 1, 2] .
EBV has two distinct life styles: latency and lytic cycles. A limited number of viral genes are expressed during latency. During lytic cycles, the majority of viral genes are expressed and virions are produced. The switch from latency to lytic cycles is regulated by two immediate-early proteins ZEBRA (Zta, EB1) and Rta, which are encoded respectively by the BZLF1 and BRLF1 genes [3] . ZEBRA and Rta synergistically activate expression of many downstream viral target genes, resulting in synthesis of early antigen (EA) and viral capsid antigen (VCA), finally engendering production of the progeny virus [4] . ZEBRA is a member of the basic zipper (bZIP) group of transcriptional activators like mammalian cellular members c-Fos and c-Jun [5] . ZEBRA binds to canonical AP-1 sites as well as ZEBRA response element (ZRE) in promoters of viral and cellular genes and activates their transcriptions [5] [6] [7] [8] . ZEBRA auto-regulates its own promoter and BRLF1 promoter [4] . A second transactivator, Rta, is also a DNA sequence-specific acidic transactivator. It has distant homology to c-myb [9, 10] . VCA is the immunological term for proteins encoded by late genes that are expressed after EBV DNA synthesis [11] .
The serine/threonine kinase Akt is a crucial regulator of cell growth, survival, and apoptosis [12] . Akt activation by cytokines and growth factors is mediated through a phosphatidylinositol 3-kinase (PI3-K)-dependent mechanism [13] . The PI3-K/Akt pathway is putatively involved in various malignancies [14] . In EBV-immortalized B cells, PI3-K/Akt pathway plays a role in both cell survival and proliferation [15] . The effect of PI3-K/Akt pathway is cooperative with EBV proteins. Latent membrane protein (LMP) 2A activates the PI3-K/Akt pathway, which leads to inhibition of TGF-b-induced apoptosis in BL cell lines and in gastric carcinoma cell lines [16] , and contributes to generation of EBV-associated cancers by regulating bcatenin signaling [17] . LMP1 also activates the PI3-K/Akt pathway to promote cell survival [18] . BRLF1, but not BZLF1, requires PI3-K/Akt activation for lytic EBV infection [19] . A recent study indicates that PI3-K is a determinant of responsiveness to B cell antigen receptor (BCR)-mediated EBV activation [20] . However, the contribution of PI3-K/Akt pathway to cell growth and to spontaneous EBV reactivation in EBV-positive BL is not well known.
P3HR-1 cell line is an EBV-positive BL cell line that is spontaneously EBV-reactivated and produces the virus [21, 22] . The study of the EBV lytic cycle originated from P3HR-1 cells [23] [24] [25] ; ZEBRA was found to be the EBV replication activator in the cells [26, 27] . This study specifically addressed the characterization of PI3-K/Akt pathway on cell growth and EBV reactivation in P3HR-1 cells to elucidate the effects of PI3-K/Akt pathway on EBV-positive BL.
Materials and methods

Cell lines and culture
Ramos [28] and BJAB [29] are EBV-negative BL cell lines. Raji [30] , P3HR-1 [21] , Akata [31] and Daudi [32] are EBV-positive BL cell lines. Cells were grown in RPMI 1640 (Nissui Pharmaceutical Co. Ltd., Tokyo, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS), streptomycin (100 lg/ml) and penicillin (100 U/ml) in 5% CO 2 at 37°C. Cells were passaged at intervals of every 4-5 days. For each experiment, cells were washed twice with phosphate buffered saline (PBS) to eliminate the effect on Akt phosphorylation of growth factors or cytokines in the spent medium.
Antibodies and inhibitors
Anti-phosphorylated Akt (serine 473) antibody, anti-Akt antibody, and PI3-K specific inhibitor LY294002 were purchased from Cell Signaling Technologies (Beverly, MA, USA). LY294002 was solubilized in dimethyl sulfoxide (DMSO) and added in medium at the indicated concentrations. Anti-ZEBRA antibody was developed in our laboratory. Anti-Rta and anti-VCA antibodies were purchased from Argene (Varilhes, France).
Cell-growth assay
Cell growth was assayed by the incorporation of MTT dye (Chemi-Con Int'l. Inc., Temecula, CA, USA). Cells were seeded in 96-well plates (Corning Inc., Corning, NY, USA) at 5·10 4 cells/100 ll per well. We added 10 ll of MTT solution (5 mg/ml) to each well, and the plates were incubated for 4 h at 37°C. We added 100 ll of isopropanol with 0.04 N HCl to each well and mixed it by repeated pipetting. Absorbance was measured at test wavelength of 570 nm and a reference wavelength of 655 nm with micro plate reader (Model 550; Bio-Rad laboratories Inc., Richmond, CA, USA). Each experiment was carried out in triplicate.
Western blot analysis
Cells were washed twice with PBS and suspended in 250 ll of ice-cold PBS/10% trichloroacetic acid, incubated on ice for 15 min and centrifuged at 15,000 rpm, 0°C for 5 min. The pellets were lysed in 50 ll lithium dodecylsulfate sample buffer [125 mM Tris-HCl pH 6.8, 2.3% (w/ v) LDS, 10% (w/v) glycerol, 5% (w/v) 2-mercaptoethanol, 10 lg/ml bromophenol blue], neutralized with 2 M TrisHCl (pH 12), then boiled for 5 min. Protein levels were quantified using a BIO-RAD protein assay (Bio-Rad Laboratories Inc., Hercules, CA, USA). These samples were resolved using SDS-polyacrylamide gel electrophoresis (PAGE), transferred to a PVDF membrane (Millipore Corp., Bedford, MA, USA), and blocked with 5% skim milk at room temperature for 1 h. Membranes were reacted with primary antibodies diluted at 4°C for over night as follows [phospho-Akt, total Akt, 1:1000; ZEBRA, Rta, 1:100; EA-D, 1:1500; b-tubulin, 1:1000]. Subsequently, they were reacted with horseradish peroxidase-conjugated secondary antibody (1:2000) at room temperature for 1 h. Following these reactions, the bands were revealed using an ECL detection Kit (Amersham Biosciences, Buckinghamshire, UK).
Immunofluorescence for detection of VCA Cells were washed by PBS, smeared on glass slides and fixed using acetone for 10 min at )20°C. The smear was incubated for 30 min with an anti-VCA antibody (1:40) followed by 30 min with FITC-goat-anti-mouse Ig (Cappel). After the reaction, the slides were washed and mounted in 1:1 glycerol/PBS. Then they were observed using a fluorescence microscope.
Reverse transcription (RT)-PCR-Southern blotting
RNA was isolated by TRIzol regent (Gibco BRL Life Technologies) according to the manufacturer's protocol. RT was performed using B CA BEST TM RNA PCR Kit Ver.l.l (Takara Bio Inc., Kyoto, Japan), according to the manufacturer's protocol. cDNA was synthesized from 1 lg of total RNA using random 9 mer and B CA BEST polymerase. PCR was carried out for BRLF1 to immediateearly gene expression and for LMP1 and LMP2A to latent gene expression. The sequences of sense, antisense primers and probes are described previously [33] . PCR conditions are shown. [BRLF1; 10 s of denaturation at 94°C, 5 s of annealing at 57°C, and 10 s of extension at 72°C for 28 cycles.] PCR product was subjected to electrophoresis on 1.5% agarose gel and transferred onto-Hybond N+nylon membrane (Amersham Parmacia Biotech, Tokyo, Japan). The membrane was prehybridized for 1-2 h at 42°C, and then hybridized with [c- 32 P] ATP-labeled probe for 20-24 h. The membrane was washed in 2·SSC-0.1% SDS at 50°C and autoradiography was carried out. Expression of b-tubulin was analyzed as an internal control. The primers sequences were described in previous study [34] . The PCR condition was 15 s of denaturation at 95°C, 15 s of annealing at 60°C, and 15 s of extension at 72°C for 24 cycles. PCR product was subjected to electrophoresis on 1.0% agarose gel and revealed using ethidium bromide staining.
Results
Phosphorylation of Akt in BL cell lines
Phosphorylation of Akt was analyzed in EBV-positive (Raji, P3HR-1, Akata, and Daudi) and EBV-negative (Ramos and BJAB) cell lines (Fig. 1 ). Cells were cultured in medium with or without FBS for 48 h and subjected to Western blotting to test the effects of FBS on the phosphorylation. The phosphorylation levels of Akt were different among cell lines. Akt phosphorylation was detected in BJAB, P3HR-1, Akata and Daudi, but not in Ramos and Raji. P3HR-1 cells had a strong Akt phosphorylation. Phosphorylation was markedly reduced in BJAB, Akata and Daudi (P < 0.05), but only slightly reduced in P3HR-1 (P=0.1346) by serum starvation. The result indicates that Akt phosphorylation is different among cell lines and is not dependent upon EBV infection; the presence of FBS is a critical factor in most cell lines except for P3HR-1.
Akt phosphorylation and cell growth of P3HR-1 cells P3HR-1 cells were cultured with or without FBS for 3 days to test the effects of FBS on Akt phosphorylation. Akt phosphorylation was analyzed using Western blotting (Fig. 2a) . The total Akt expression and the level of Akt phosphorylation were quite similar in both cultures. Akt phosphorylation was slightly detected in Day 0; it Whole cell lysates were separated by SDS-PAGE; total Akt (tAkt) and phosphorylated Akt (pAkt) were analyzed respectively with anti-Akt and anti-phospho-Akt antibodies, using Western blotting. The levels of Akt phosphorylation and total Akt were measured using laser densitometry; the relative ratio was determined. The statistical differences were analyzed by Student's t test (*P < 0.05). The means -SD of two independent experiments are shown We analyzed the effects of FBS on cell growth of P3HR-1 cells using MTT assay (Fig. 2b) . The growth curves were similar in cells cultured in the medium with and without FBS for 3 days (P = 0.1694). These results suggested that P3HR-1 cells might have their own autocrine system, which promotes cell growth in serum starvation conditions.
LY294002 inhibits Akt phosphorylation and the cell growth
Phosphorylation of Akt is regulated by PI3-K (13). Effects of a PI3-K specific inhibitor, LY294002, on the phosphorylation of Akt were analyzed using Western blotting (Fig. 3a) . Cells were cultured with LY294002 (0, 2, 10, or 50 lM) in FBS free medium for 24 h. They were tested for Akt phosphorylation. Phosphorylation was inhibited in a dose-dependent manner. The result indicates that Akt phosphorylation of P3HR-1 cells is mediated by PI3-K, which is inhibited by LY294002.
The effect of LY294002 on cell growth of P3HR-1 in FBS free medium was examined using MTT assay (Fig. 3b) . Cell growth was inhibited by LY294002 in a dose-dependent and time-dependent manner (P < 0.05). These results suggest that PI3-K/Akt signaling pathway can promote growth of P3HR-1cells in FBS free medium.
LY294002 inhibits specifically EBV reactivation
It was reported that PI3-K was activated on B cell receptormediated EBV reactivation [20] . Expressions of lytic proteins were analyzed for the spontaneous EBV reactivation in P3HR-1 cells to investigate the association of PI3-K/Akt pathway with EBV reactivation. Cells were cultured with LY294002 (0, 2, 10, or 50 lM) in medium without FBS for 24 h. Expressions of immediate-early proteins ZEBRA and Rta, and an early protein EA-D were analyzed using Western blotting (Fig. 4a) . ZEBRA expression was not affected by the treatment. However, Rta and EA-D expressions were clearly decreased in a dose-dependent manner. The late protein VCA was analyzed for 24 h using immunofluorescence (Fig. 4b) . VCA-positive cells were The mRNA of BRLF1 was quantitatively analyzed by RT-PCR analysis (Fig. 5) to determine the stage of LY294002 inhibition of Rta expression (Fig. 4a) . Cells were cultured with LY294002 in FBS free medium for 12 h. Expression of BRLF mRNA was dose-dependently inhibited by the treatment (P < 0.05). The result indicates that PI3-K/Akt regulates Rta at the transcriptional level.
Discussion
We analyzed Akt phosphorylation in EBV-positive (Raji, P3HR-1, Akata and Daudi) and EBV-negative (Ramos and BJAB) BL cell lines. Results show that Akt was phosphorylated in BJAB, P3HR-1, Akata and Daudi cells, but not in Ramos and Raji cells (Fig. 1) . We infer that Akt phosphorylation is unrelated to EBV infection status. The Akt phosphorylation was strongest in P3HR-1 and moderate in BJAB, but weak in Akata and Daudi cells. The Akt phosphorylation and cell growth in BJAB, Akata and Daudi cells was reduced in cultures without FBS, but not in P3HR-1 cells. The phosphorylation in P3HR-1 cells was not dependent on supplementation of FBS, indicating that P3HR-1 cells have their own Akt activation systems. Therefore, we specifically examined Akt phosphorylation for cell growth and EBV spontaneous reactivation on P3HR-1 cells.
We demonstrate that Akt is constitutively phosphorylated in P3HR-1 cells, and that PI3-K/Akt signaling pathway upregulates cell growth and EBV lytic cascade. LY294002, a PI3-K specific inhibitor, doso-dependently downregulates Akt phosphorylation and cell proliferation. Lytic proteins Rta, EA-D and VCA, but not ZEBRA, were inhibited by LY294002.
We supposed what kind of proteins could activate the Akt in P3HR-1 cells. LMP1 and LMP2A activate the PI3-K signaling pathway in EBV-infected B cell lines [16] [17] [18] . We confirmed that LMP1 and LMP2A mRNA were detected in P3HR-1 cells by RT-PCR; however, LMP1 protein is inferred to be expressed very slightly or not at all in P3HR-1 cells (data not shown). The P3HR-1 viral genome lacks EBNA2 and EBNA-LP coding regions, which are critical for LMP1 gene transcription [36] . A recent study demonstrated that EBV induces CD40L in B cells [37] and that the interaction of CD40/CD40L might activate PI3-K/ Akt pathway [38] . Further, IL-10 is a cytokine that EBVpositive BL cells produce predominantly as the autocrine growth factor [39] and is capable of PI3-K activation [40] . Although we detected CD40, CD40L and IL-10 expressions in P3HR-1 cells, the effect of CD40/CD40L interaction or IL-10 to PI3-K/Akt activation was not detected by the blocking test using each antibody (date not shown). LMP2A might be the factor in activation of PI3-K/Akt pathway in P3HR-1 cells.
We considered how PI3-K/Akt promotes cell growth of P3HR-1 cells in serum without FBS. Akt is a serine/threonine kinase that mediates many downstream events regulated by PI3-K [13, 14] . Our study demonstrated that PI3-K specific inhibitor LY294002 inhibited the growth of P3HR-1 cells (Fig. 3b) . Cell viability was reduced and the level of cleaved-caspase-9 was increased dose-dependently when cells were treated with LY294002, whereas the p27Kip1 level was not changed (data not shown). These data suggest that growth inhibition of P3HR-1 cells by LY294002 resulted from the apoptosis rather than cell cycle arrest by p27Kip1. PI3-K/Akt pathway might promote P3HR-1 cell growth by suppressing the apoptotic signal. We demonstrated that the PI3-K/Akt pathway is associated with spontaneous EBV reactivation in P3HR-1 cells. P3HR-1 is a well-known EBV-producing cell line that ZEBRA is constitutively expressed in the cells [21] . Surprisingly, the PI3-K specific inhibitor LY294002 blocked expression of Rta, EA-D and VCA, but not ZEBRA (Fig. 4) . ZEBRA is an immediate-early transcriptional factor that triggers the switch from the latent to lytic cycle [3] . ZEBRA transactivates BRLF1 (Rta) promoters [4] . ZEBRA synergizes with Rta, engendering expression of EA-D, EBV DNA synthesis, VCA expression, and ultimately, virion production [4] . Our results indicate that the PI3-K/Akt pathway is associated with the EBV lytic cascade downstream of ZEBRA. Inhibition of Rta by LY294002 occurred at the transcriptional level (Fig. 5) . Although PI3-K/Akt pathway was shown to be involved in EBV replication previously, the reactivation was compulsory induced by transduction of lytic gene to the cell or by exogenous stimuli such as anti-human IgG antibody [19, 20] . This is the first report showing that spontaneous EBV reactivation in P3HR-1 cells could be induced via PI3-K/ Akt pathway.
LY294002 downregulates transcription of BRLF1 gene and inhibits the EBV reactivation cascade. What kind of EBV proteins are the targets of Akt? ZEBRA is a phosphoprotein [41] [42] [43] . Phosphorylation of ZEBRA plays a crucial role in disruption of EBV latency. ZEBRA can be phosphorylated in vitro by several isoforms of protein kinase C (PKC) and by casein kinase (CK2) [41, 42, 44] . The consensus sites for phosphorylation by PKC are at threonine (T)159 and serine (S)186 of ZEBRA. The phosphorylation sites by CK2 are at S167 and S173. ZEBRA (S186A) mutant is deficient in its capacity to activate the Rta promoter [45] . We hypothesize that Akt can phosphorylate known or unknown sites in ZEBRA, and that phosphorylation of ZEBRA engenders activation of BRLF1 promoter and regulates the lytic cycle. An optimal phosphorylation motif for Akt is R-x-R-x-x-(S/T)-x, Fig. 4 (a although not all the substrate of Akt is applied to the motif [12] . ZEBRA has a phosphorylation motif for Akt in that contains S186. Interestingly, Rta also has this motif with the peptides sequence of R-V-R-A-Y-T 153 -Y. That fact suggests that Akt phosphorylates ZEBRA and/or Rta. It remains in future to be studied whether Akt phosphorylates ZEBRA or/and Rta on EBV reactivation system. Anti-cancer drugs such as 5-bromodeoxyuridine [46] and neocarzinostatin [47] usually reactivate EBV on cell growth arrest [48] [49] [50] . Hydroxyurea can eliminate the EBV genome in BL cell lines, but induce hydroxyurea resistance for the treated cells [51, 52] . However, LY294002 specifically inhibits PI3-K along with both cell growth and EBV reactivation. PI3-K/Akt pathway might be a good target for therapy to PI3-K/Akt activated EBV associated tumors cells, such as P3HR-1 cells.
In conclusion, our study demonstrates that P3HR-1 cells use the PI3-K/Akt system effectively for cell growth and spontaneous EBV reactivation. LY294002 inhibits cell growth and EBV reactivation at a critical stage, indicating that PI3-K might be a good molecular target for therapy of certain EBV associated diseases. 
